Previous close | 6.84 |
Open | 7.00 |
Bid | 6.73 x 300 |
Ask | 6.76 x 400 |
Day's range | 6.72 - 7.24 |
52-week range | 3.25 - 10.45 |
Volume | |
Avg. volume | 1,148,377 |
Market cap | 570.484M |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.50 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.67 |
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.
Key Insights Significant control over Anavex Life Sciences by individual investors implies that the general public has...